Inhibits NRF2 signaling, sensitizing cancer cells (e.g., hepatocellular carcinoma) to chemotherapy and anti-tumor drugs by blocking the NRF2–ARE activation pathway. The gene discussed is NFE2L2; the disease is neoplasm.